Pramoolsinsap C, Busagorn N, Kurathong S
Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
J Med Assoc Thai. 1996 Nov;79(11):681-8.
Clinical and laboratory findings were studied in 56 patients with liver disease (10 acute hepatitis, 10 fulminant hepatitis and 36 cirrhosis). Spontaneous bleeding occurred in 19 patients (8 fulminant hepatitis, 11 cirrhosis) and another 8 cirrhotic patients had variceal bleeding. There were 22 deaths (36%), 12 of these patients had spontaneous bleeding. Depletion of antithrombin III (AT III) occurred in fulminant hepatitis (mean +/- S.D. = 27 +/- 16%) and cirrhosis (49 +/- 23%) but thrombin-antithrombin III complexes (TAT) were significantly higher in the former (45 +/- 22 vs 8.6 +/- 7.0 ng/ml; p = 0.006). Within subgroups of cirrhosis (with or without spontaneous bleeding or with variceal bleeding), there were no significant differences in levels of AT III or TAT. Of all patients, those with spontaneous bleeding had persistently lower AT III levels but had variable changes of other coagulation parameters (PT, PTT, TT, FDP, fibrinogen and platelet counts). This study showed that coagulopathic consumption is an important cause of AT III deficiency in fulminant hepatitis but not in cirrhosis. Serial changes in AT III levels correlated with bleeding risk in patients with liver disease.
对56例肝病患者(10例急性肝炎、10例暴发性肝炎和36例肝硬化)的临床和实验室检查结果进行了研究。19例患者发生自发性出血(8例暴发性肝炎,11例肝硬化),另有8例肝硬化患者发生静脉曲张出血。有22例死亡(36%),其中12例患者有自发性出血。抗凝血酶III(AT III)在暴发性肝炎(均值±标准差=27±16%)和肝硬化(49±23%)中出现消耗,但凝血酶 - 抗凝血酶III复合物(TAT)在前者中显著更高(45±22对8.6±7.0 ng/ml;p = 0.006)。在肝硬化亚组(有或无自发性出血或有静脉曲张出血)中,AT III或TAT水平无显著差异。在所有患者中,有自发性出血的患者AT III水平持续较低,但其他凝血参数(PT、PTT、TT、FDP、纤维蛋白原和血小板计数)有不同变化。本研究表明,凝血病性消耗是暴发性肝炎中AT III缺乏的重要原因,但不是肝硬化的原因。AT III水平的系列变化与肝病患者的出血风险相关。